High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival (original) (raw)
Related papers
Expression of YKL-40, an Inflammatory Glycoprotein and its Prognostic Implications in Cancer
Journal of Molecular Biomarkers & Diagnosis, 2012
A cancer prognosticator refers to a substance or process that is a sign of the existence of cancer in the body and foretelling the course of cancer. It might be either a molecule oozed by a tumor or it can be a specific response of the body to the occurrence of cancer. YKL-40 is an inflammatory glycoprotein and a member of mammalian chitanaselike proteins (CHI3L1), is expressed and secreted by several types of solid tumor cells, inflammatory cells and stem cells. The precise physiological role of YKL-40 in cancer is not still clear and suggested that it has a role in cancer cell proliferation, differentiation, metastatic potential, cell attachment and migration, reorganization and tissue remodeling. Several clinical studies of patients with diverse types of cancer indicated that elevated serum level of YKL-40 may be a prognostic marker of cancer. The higher level of YKL-40 in serum also seems to correlate with short survival and poorer prognosis of several cancers including breast, ovary, colorectal, and glioblastoma melanoma. Serum YKL-40 level is often elevated compared to healthy subjects, in patients with disease characterized by inflammation, and increased extracellular remodeling or ongoing fibrosis such as infections. This review depict the present facts regarding YKL-40 and talk about its relation in cancer prediction.
High serum YKL-40 level in patients with small cell lung cancer is related to early death
Lung Cancer, 2004
YKL-40, a growth factor for connective tissue cells, is secreted by cancer cells and macrophages. Elevated serum YKL-40 in patients with metastatic carcinoma has been associated with poor prognosis. We evaluated serum YKL-40 in 131 patients with small cell lung cancer (SCLC). Twenty-two percent of the patients with limited disease and 40% of the patients with extensive disease had elevated serum YKL-40. The median survival was 5.1 months for patients with elevated serum YKL-40 and 9.0 months for patients with normal serum YKL-40. Patients with elevated serum YKL-40 had increased hazard for death within the first 6 months after the start of chemotherapy compared to patients with normal serum YKL-40 (HR = 2.06, P = 0.009). Multivariate Cox analysis including routine prognostic variables showed that serum YKL-40 (P = 0.02) is independent of prognostic variables for survival within the first 6 months. Studies are needed to determine the function of YKL-40 in SCLC.
Prognostic effect of serum and tissue YKL-40 levels in bladder cancer
Urologic Oncology: Seminars and Original Investigations, 2014
Objectives: YKL-40 is a novel inflammatory serum protein shown to be associated with the presence and prognosis of several malignancies. However, its prognostic relevance has not yet been analyzed in bladder cancer (BC). Therefore, the aim of this study was to assess the tissue, serum, and urinary levels of YKL-40 and their prognostic value in BC.
High serum YKL-40 level is associated with poor prognosis in patients with lung cancer
Tuberkuloz ve Toraks
High serum YKL-40 level is associated with poor prognosis in patients with lung cancer Introduction: YKL-40 is a glycoprotein that plays role in inflammation and malignant processes. High serum YKL-40 levels are associated with short survive in cancer and chronic obstructive pulmonary disease (COPD) is another reason to increase its' level. However, limited knowledges are known in YKL-40 along with lung cancer and COPD. Materials and Methods: One hundred patients were involved to study with lung cancer (84 men, 16 women, and median age 62). Results were compared with 30 healthy volunteers. Thirteen patients were small cell lung cancer (SCLC), 87 patients were nonsmall cell lung cancer (NSCLC). 62% of patients were inoperable.
Scandinavian journal of urology, 2017
YKL-40 is an inflammation-associated glycoprotein supposed to have a role in cell survival and angiogenesis. Renal cell carcinoma (RCC) is characterized by varying prognosis and risk of relapse after a disease-free period of years. Prognostic markers are critically needed. This study investigated whether YKL-40 could be a useful biomarker in RCC patients. Blood samples from 82 patients with RCC were collected at the time of diagnosis and 3, 5 and 9 months and 2 and 3 years after nephrectomy. YKL-40 levels were determined by enzyme-linked immunosorbent assay. Survival of patients and relapse of RCC were followed up to 15 years. Circulating YKL-40 levels were increased in patients with metastatic RCC at the time of diagnosis (median 115.7 ng/ml, interquartile range 61.0-221.6 ng/ml). Among patients primarily diagnosed with non-metastatic RCC, baseline YKL-40 levels were significantly higher in patients who experienced a relapse during follow-up (103.7, 59.3-242.0 ng/ml) than in patien...
High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival
Oncology Reports, 2003
YKL-40 (human cartilage glycoprotein-39) is a member of family 18 glycosyl hydrolases. YKL-40 is a growth factor and is secreted by cancer cells. High serum levels of YKL-40 in patients with colorectal cancer and recurrent metastatic breast cancer have been associated with a poor prognosis. We evaluated the prognostic value of plasma YKL-40 in patients with primary ovarian cancer (OC). YKL-40 was determined by ELISA in plasma obtained preoperatively from 47 women with stage III OC and in plasma from 79 healthy females. The results showed that plasma YKL-40 was elevated compared to healthy females in 57% of the OC patients and was highest in the patients who died during the follow-up compared to the patients still alive (186 vs. 78 µg/l, p=0.002). Patients with high plasma YKL-40 (>130 µg/l) had significantly (p=0.0003) shorter survival than patients with normal plasma YKL-40. Multivariate Cox regression analysis showed that plasma YKL-40 (RH=3.95; 95% CI, 1.52-10.27; p=0.005) and radicality after primary surgery (RH=4.03; 95% CI, 1.81-8.97; p=0.001) were independent prognostic factors of survival, whereas age, histological type of tumour and serum CA125 had no independent prognostic value. In conclusion, plasma levels of YKL-40 proved of prognostic value in stage III OC patients.
Serum YKL-40 Levels in Patients with Esophageal Squamous Cell Carcinoma
Cancer Growth and Metastasis, 2011
Aims and background: YKL-40 is a glycoprotein secreted by macrophages, neutrophils and malignant tumor cells. YKL-40 is expressed and secreted by several types of tumors. The aim of this study examined the clinical usefulness of YKL-40 for detection in esophageal squamous cell carcinoma (ESCC). Methods: Using ELISA kits, we measured the concentration of YKL-40 in serum from 100 patients with ESCC and compared this concentration with healthy population. Results: We found significantly higher serum levels of YKL-40 in patients with ESCC compared to the healthy population (P , 0.0001). Conclusions: These results suggested that regarding serum YKL-40 as a tumor marker could be benefical in the early clinical diagnosis.
Serum YKL-40 and bone marrow angiogenesis in multiple myeloma
International Journal of Cancer, 2009
In a recently published study, Saidi et al. showed that elevated levels of CHI3L1 mRNA, encoding the secreted glycoprotein YKL-40, are associated with poor survival in glioblastoma, probably by promoting angiogenesis. 1 A role for YKL-40 in angiogenesis is supported by a few in vitro studies on the porcine YKL-40 analogue, gp38k, showing 84% sequence homology with human YKL-40. 2 Gp38k is secreted by differentiating vascular smooth muscle cells 2 and besides modulating adhesion and migration of these cells, 3 gp38k stimulates both directional migration of human umbilical vein endothelial cells (HUVEC), at a level comparable to that achieved with the endothelial cell chemoattractant basic fibroblast growth factor (bFGF), 4 and reorganisation of HUVEC with the formation of branching tubules. 4 Angiogenesis plays a central role in the pathogenesis and progression of solid tumours. In recent years, there has been growing evidence that bone marrow (BM) angiogenesis exerts a similar role in certain hematological malignancies, including multiple myeloma (MM). As seen in glioblastoma and several other types of solid tumours, 6,7 a subgroup of patients with MM display elevated levels of serum YKL-40 associated with a more aggressive course of the disease, 8 but a possible role for YKL-40 in the biology of MM remains to be established. Inspired by the study from Saidi et al., we have investigated the association between serum YKL-40 and the degree of BM angiogenesis in 45 patients with newly diagnosed MM. Patient characteristics included age (median 67 years; range, 44-83 years), gender (49% male; 51% female), M-protein isotype (69% IgG; 20% IgA; 9% light chains only; 2% nonsecretory), and stage according to the International Staging System ISS (19% stage I; 49% stage II; 32% stage III). Thirty-six patients received conventional treatment, and 9 patients received high-dose chemotherapy followed by autologous stem cell transplantation. Serum concentrations of YKL-40 were determined in duplicates using a sandwich-type enzyme-linked immunosorbent assay (ELISA) (Quidel 1 , Santa Clara, CA). 8 BM angiogenesis was estimated as microvessel density (MVD), as previously described. The angiogenic cytokines bFGF, hepatocyte growth factor (HGF) and interleukin-6 (IL-6) were measured in serum, also as previously described. The study was approved by the local ethical committee and performed in accordance with the Helsinki II declaration.